Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$362.56 0.85 (0.23)%
Market Cap 37.55B
01/20/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent® (alirocumab) InjectionRead on
Sanofi and Regeneron Provide Update on Ongoing Patent Litigation Regarding Praluent® (alirocumab) InjectionRead on